Australia markets closed

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.1900+0.0100 (+0.85%)
At close: 04:00PM EST
1.1900 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.1800
Bid1.1700 x 2900
Ask1.1900 x 1800
Day's range1.1600 - 1.2000
52-week range0.6500 - 2.1700
Avg. volume2,366,347
Market cap485.867M
Beta (5Y monthly)2.06
PE ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings date29 Feb 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.31
  • GlobeNewswire

    Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

    DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Patrick Holt, President & CEO, and members of Amarin’s senior management team to discuss its fourth quarter and year end 2023 results on Thursday, February 29th, 2024, at 8:00 a.m. ET. The call will include brief remarks on 2023 highlights followed by Q&A. The conference call with management will follow the release of the Company’s

  • Zacks

    5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates

    Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.

  • GlobeNewswire

    Amarin Chairman & CEO Issue Letter to Shareholders

    DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Chairman of the Board, Odysseas Kostas, M.D., and President & CEO, Patrick Holt, issued the following letter to Amarin shareholders: Dear Fellow Amarin Shareholders, 2023 was an important year for Amarin, marked by necessary transition and change. With a new board focused on shareholders, we undertook significant actions to strengthen the Company. We re